Cardioprotective Effect of Ghrelin in Cardiopulmonary Bypass Involves a Reduction in Inflammatory Response

Yukun Cao1*, Jun Tang2*, Ting Yang3*, Heng Ma1, Dinghua Yi1*, Chunhu Gu1*, Shiqiang Yu1*

1 Department of Cardiovascular Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province, China, 2 Department of Anesthesiology, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi Province, China, 3 Department of Oral Anatomy and Physiology and TMD, School of Stomatology, Fourth Military Medical University, Xi'an, Shaanxi Province, China

Abstract

Background: Ghrelin has been reported to protect the cardiovascular system; however, the cardioprotective effect of ghrelin against cardiopulmonary bypass (CPB) induced myocardial injury are unclear. In this study, the protective effect of ghrelin on CPB induced myocardial injury and the underlying mechanisms were investigated.

Methods and Results: Adult male rats were subjected to CPB and randomly to receive vehicle (n = 8), ghrelin (n = 8), ghrelin plus [D-Lys3]-GHRP-6, a GHSR-1a inhibitor (n = 8), or ghrelin plus wortmannin, a phosphoinositide 3-kinase (PI3K) inhibitor (n = 8). In vitro study was performed on cultured cardiomyocytes subjected to simulated cardiopulmonary bypass (SCPB). Ghrelin attenuated the inflammatory response, as evidenced by reduced induction of TNF-α, IL-6 and myocardial myeloperoxidase activity and concurrent reduction in apoptosis, oxidative stress, and levels of myocardial injury markers following CPB. Moreover, ghrelin significantly increased cardiac function after CPB. In cultured cardiomyocytes subjected to simulated CPB, ghrelin increased cell viability and decreased the percentage of apoptotic myocytes. Inhibition of ghrelin downstream signaling blocked the cardioprotective effects both in vivo and vitro.

Conclusions: Ghrelin could provide an effective approach to the attenuation of CPB induced myocardial injury. The cardioprotective effects elicited by ghrelin may contribute to the inhibition of inflammatory response through the Akt-activated pathway.

Introduction

Open heart surgery with cardiopulmonary bypass (CPB) is associated with both acute systemic and myocardial inflammatory responses, which have implications for postoperative myocardial function and recovery [1]. In addition, the heart itself is a source of inflammatory mediators and reactive oxygen species that are likely to contribute to the impairment of cardiac pump function [2]. Despite significant changes and improvements in surgical techniques, inflammation remains a significant clinical problem. Therefore, the complementary and alternative medicine to control the inflammatory response continues to be the focus of extensive experimental research and clinical studies [3].

Ghrelin is a 28-amino-acid acylated peptide, produced primarily by the X/A-like enteroendocrine cells of the stomach that has been identified as the endogenous ligand for the growth hormone secretagogue receptor (GHSR) [4]. Within cardiovascular system, two GHS-R subtypes, GHS-R1a and GHS-R1b, are present in the heart and in the vessels [5], indicating a potential role of ghrelin in regulating cardiovascular function. Stimulation of GHSR prevents cardiac damage after ischemia/reperfusion in hypophysectomized rats [6]. Moreover, administration of ghrelin improved cardiac function and reduced myocardial injury induced by ischemia and reperfusion in the isolated rat heart, effects that were independent of growth hormone secretion and have been related to protein kinase C activation [7,8]. Ghrelin attenuates the inflammatory response in endotoxic shock [9,10], stroke [11,12], and acute myocardial infarction [13]. In particular, ghrelin has been shown to alleviate LV dysfunction and ventricular remodeling post-MI in the rat, by inhibiting the inflammatory response [14,15]. These observations have indicated that ghrelin functions as an anti-inflammatory molecule, although the underlying mechanisms remain elusive.

Tumor necrosis factor (TNF-α) and interleukin (IL)-6 are both important and potent pro-inflammatory cytokines. TNF-α is an important pro-inflammatory factor, which is able to activate other inflammatory cytokines and induce the expression of adhesion molecules. IL-6 is responsible for the coordination of the acute phase response and plays a positive role in the local inflammatory reaction by amplifying leukocyte accumulation [16,17]. Elevated levels of serum TNF-α and IL-6 have been reported in patients with ischemia/reperfusion injury, chronic heart failure, and viral myocarditis [18,19,20]. However, whether ghrelin decreases
inflammatory response, especially TNF-α and IL-6 induction, in CPB induced myocardial inflammatory injury, has not been previously explored. Inflammatory response and cytokine production are particularly active after CPB and contribute to the development of cardiac dysfunction [21]. Cytokines such as TNF-α and IL-6 released after CPB induced myocardial inflammatory injury can acutely regulate myocyte survival or death and trigger subsequent cellular inflammatory response. Moreover, both TNF-α and IL-6 exert direct negative inotropic effects on the heart, that can contribute to myocardial dysfunction in several pathological conditions [22,23]. In the present study, accordingly, we investigated whether ghrelin attenuates myocardial injury induced by cardiopulmonary bypass and explored the mechanisms underlying this protection.

Materials and Methods

Animals and Cardiopulmonary Bypass Model

The experiments were performed in adherence with the National Institutes of Health Guidelines for the Use of Laboratory Animals and were approved by the Fourth Military Medical University Committee on Animal Care. Male Sprague–Dawley rats (14 weeks old, 450–550 g) were used for the experiments (n = 8/group). The rat cardiopulmonary bypass model was developed according to Dong and colleagues with some modifications [24,25]. Rats were anesthetized with butyrolactone (60 mg/kg, intraperitoneal administration) at the beginning, and additional butyrolactone was used to maintain anesthesia. The right femoral artery was cannulated for arterial pressure monitoring. After administration of heparin (250 U/kg), a 16 gauge catheter, modified to a multiside-orifices cannula in the forepart, was inserted into the right jugular vein and advanced to the right atrium. This approach was used as a vein drain line in CPB. A 22 gauge catheter for arterial infusion was introduced into tail artery. The mini-cardiopulmonary bypass circuit comprised a venous reservoir (10 ml), a specially designed membrane oxygenator, and a roller pump (BT00-300M, Lange Co, Shanghai, China). All components were connected with polyethylene tubing. Body central temperature was monitored with a rectal probe and kept at 36.5°C to 38.3°C by a heat lamp placed around the animal and the CPB equipment. The circuit was primed with 10 mL of a solution of heparin 1 ml (250 U/kg), synthetic colloid 8 ml and sodium bicarbonate 1 ml. At the initiation of perfusion, the ow rate was gradually increased to 100 ml/kg/min and maintained for 60 min; it was then turned down step by step to maintain hemodynamic stability. As the rat was weaned from CPB, the tail artery catheter was removed, and the right jugular vein catheter was drawn back to the superior vena. The remaining priming solution was infused gradually when the main arterial pressure was less than 60 mm Hg. After 1 h of intensive postoperative care, the right jugular vein catheter and the femoral artery catheter were decannulated. Then the neck, tail, and groin incisions were sutured. Throughout the experiment, the mean arterial pressure was maintained about 60 to 80 mm Hg.

Before the start of CPB, rats randomly received one of the following treatments: Sham group (only cannulated for cardiopulmonary bypass but not undergoing cardiopulmonary bypass); Control group (intravenous injection; saline); Ghrelin group (intravenous infusion at 60 µg/kg per h ghrelin from 10 min before the start of CPB to the end of the experiment, Phoenix Pharmaceuticals, Burlingame, GA, USA); ghrelin plus [D-Lys3]-GHRP-6 (a GHSR-1a blocker, Phoenix Pharmaceuticals, USA) group (40 µg/kg intravenous injection 15 min before CPB); ghrelin plus wortmannin (a PI3K inhibitor, Sigma, USA) group (20 µg/kg intravenous injection 15 min before CPB). After 4 h of cardiopulmonary bypass, the rats were anesthetized with butyrolactone again. A micro-catheter was inserted into left ventricular through left carotid artery to measure the left ventricular developed pressure (LVDP). The artery pressure was measured by right femoral artery cannulation. Electrocardiogram (ECG) and LVDP were simultaneously recorded on a polygraph (RM-6200C, Chengdu, China). Mean arterial blood pressure (MAP), heart rate (HR), left ventricular developed pressure (LVDP), and the instantaneous first derivation of LVDP (±LVdP/dtmax) were derived by computer algorithms. After these operations for function measurement, blood samples were collected by cardiac puncturing and the heart was harvested for biochemical analysis. Plasma lactate dehydrogenase (LDH) levels were measured spectrophotometrically (DU 640; Beckman Coulter, Brea, CA). And plasma cardiac troponin I (cTnI) levels were measured by a commercially available high-sensitivity cTnl ELISA kit (Wuhao Company, Shanghai, China). All measurements were performed in duplicates.

Determination of Serum and Tissue Levels of Inflammatory Cytokines and Myocardial Myeloperoxidase Activity

After 4 h of CPB, the levels of TNF-α and IL-6 in the myocardial tissue homogenates and serum were determined with commercially available enzyme-linked immunosorbent assay (ELISA) kits (R&D Systems). All ELISA protocols were carried out according to manufacturer guidelines as described in our previous study [21]. Myeloperoxidase (MPO) activity was determined as described previously [26].

Reduced Glutathione/Oxidized Glutathione Analysis

Hearts (n = 8 per group) were rapidly excised and the left ventricles were frozen in liquid nitrogen for the glutathione assay. Samples were homogenized with a glass tissue grinder. Colorimetric determination of reduced (GSH) and oxidized (GSGG) glutathione content was performed using a commercial kit (Beyotime Institute of Biotechnology, Shanghai, China).

Cardiomyocyte Isolation and Contractions

Cardiomyocytes were enzymatically isolated from rats following CPB as described previously [27]. Myocyte yield was approximately 75%. Only rod-shaped cells with clear edges were selected for contractile study. Contractile properties of myocytes were assessed using an IonOptixTM soft-edged system [27]. Myocyte contraction was induced at a frequency of 0.5 Hz by platinum electrodes connected to an electrical stimulator. Cell shortening and relaxation were assessed using the following indices: peak shortening (PS), time-to-PS (TPS), time-to-90% relaxation (TR90), and maximal velocities of shortening/relaxation (±dL/dt).

Terminal Deoxynucleotidyl Nick-end Labeling Assay and Myocardial Caspase-3 Activity

Myocardial apoptotic index was analyzed by terminal deoxynucleotidyl nick-end labeling (TUNEL) assay as documented in a previous study [28]. The index of apoptosis was expressed by number of apoptotic myocytes/total number × 100%. And myocardial caspase-3 activity was performed by using a caspase-3 colorimetric assay kit (Chemicon, Temecula, CA) following the manufacturer’s instructions as previously documented [29]. The activity of caspase-3 was calculated using a standard curve and expressed as fold increase over the mean value of the sham CPB group.
Simulated Cardiopulmonary Bypass (SCPB)

Primary cultures of neonatal rat cardiomyocytes from one to two-day-old Sprague-Dawley rats were prepared and cultured as described previously [30]. SCPB was performed as described by Aebert with some modifications [31]. Briefly, the cardiomyocytes were transferred into the CPB buffer containing 20% CPB serum (taken from rats undergoing CPB) and incubated for 6 h in a humidified cell culture incubator (5% CO₂, 37°C). This buffer was designed to simulate the extracellular milieu of CPB, with the approximate concentrations of potassium, hydrogen, and lactate ions that occur in vivo. At the onset of SCPB culture, cardiomyocytes (n = 8/group) were randomly exposed to one of the following treatments: vehicle, ghrelin (10 nmol/L), ghrelin plus [D-Lys3]-GHRP-6 (15 nmol/L), and ghrelin plus wortmannin (10 nmol/L). Cell viability was determined with the MTT assay. After SCPB, myocyte apoptosis was determined by means of DAPI/TUNEL double-staining procedure. Among all the DAPI positive stained myocytes (n = 8/group) were randomly exposed to one of the following treatments: vehicle, ghrelin (10 nmol/L), ghrelin plus [D-Lys3]-GHRP-6 (15 nmol/L), and ghrelin plus wortmannin (10 nmol/L). Cell viability was determined with the MTT assay. After SCPB, myocyte apoptosis was determined by means of DAPI/TUNEL double-staining procedure. Among all the DAPI positive stained cardiomyocyte, the number of TUNEL-positive cells was presented as a percentage. Neither [D-Lys3]-GHRP-6 nor wortmannin, a PI3K inhibitor, resulted in myocardial injury, as evidenced by increased serum cTnI and LDH activity, myocardial apoptosis and caspase-3 activity (Fig. 2B). Ghrelin treatment significantly reduced cTnI and LDH activity (Fig. 1), myocardial apoptosis (Fig. 2A), and caspase-3 activity (all P<0.05). These effects of ghrelin were abolished by [D-Lys3]-GHRP-6, a GHSR-1a inhibitor, and Wortmannin, a PI3K inhibitor.

Immunoblotting

Total protein was extracted from both CPB cardiac tissue and SCPB myocytes, and the immunoblots were probed with an anti-pAkt (Ser-473) antibody (Cell Signaling, Santa Cruz, CA) overnight at 4°C followed by incubation with the corresponding secondary antibody at room temperature for 1 h. The blots were visualized with ECL-Plus reagent (GE Healthcare, Piscataway, NJ). pAkt immunoblots were then stripped with strip buffer at 50°C for 30 min and re-blotted for total Akt.

Statistical Analysis

All values were expressed as mean±SEM. Data were analyzed using a commercially available statistics software package (GraphPad Prism software, version 5.0, GraphPad Software, San Diego, CA, USA). For repeatedly measured parameters, comparisons between the groups were analyzed by two-way ANOVA. Otherwise, one-way analysis of variance (ANOVA) followed by Tukey’s test for post hoc analysis was adopted for comparisons. A P<0.05 was considered as statistically significant.

Results

Ghrelin Decreased Myocardial Injury and Oxidative Stress in CPB Rats

To examine whether ghrelin might reduce myocardial injury, plasma cTnl and LDH levels, myocardial apoptosis and caspase-3 activity were measured. As shown in Figs. 1 and 2, 60 min of CPB resulted in myocardial injury, as evidenced by increased serum cTnl and LDH activity (Fig. 1), myocardial apoptosis (Fig. 2A), and caspase-3 activity (Fig. 2B). Ghrelin treatment significantly reduced cTnl and LDH activity, myocardial apoptosis, and caspase-3 activity compared with the vehicle group (all P<0.05). Because CPB elicits a robust neutrophil response, we determined whether ghrelin exerted its cardioprotective effect by an anti-neutrophil mechanism. Neutrophil accumulation was determined in the CPB hearts by measuring MPO activity. As illustrated in Fig. 2C, 60 min of CPB significantly elevated MPO activity. Ghrelin treatment significantly reduced MPO activity, indicating a significant anti-neutrophil effect of ghrelin. Reduced (GSH) and oxidized (GSSG) glutathione content are considered good indicators of oxidant status. We investigated whether ghrelin was able to counteract oxidative stress in this model by detecting GSH/GSSG. GSH levels were significantly lower and GSSG significantly higher in CPB rats compared with sham-operated rats. This effect was completely reverted by ghrelin treatment, indicating that ghrelin could attenuate oxidative stress induced by CPB (Fig. 2 D and E, all P<0.05). These effects of ghrelin were abolished by [D-Lys3]-GHRP-6, a GHSR-1a inhibitor and Wortmannin, a specific PI3K inhibitor.

Ghrelin Preserved Cardiac Pump Function after CPB

As shown in Table 1, CPB decreased MAP, LVDP, +LV dP/dt max and −LV dP/dt max compared with the sham group. Treatment with ghrelin improved these parameters of cardiac function compared with the CPB group and these beneficial effects were abolished with the ghrelin inhibitor and PI3K inhibitor (P<0.05). There was no significant difference in the changes of HR between groups treated with either ghrelin or saline. These results showed that treatment with ghrelin improves cardiac systolic and diastolic function in rats subjected to CPB. We went...
on to examine the effect of ghrelin on CPB-elicited cardiomyocyte contractile response. CPB triggered an overt contractile dysfunction manifested as depressed peak shortening (PS) and maximal velocity of shortening/relaxation (±dL/dt), as well as prolonged TR90 in vehicle treated cardiomyocytes. In line with its protective effects on myocardial injury, ghrelin significantly alleviated CPB-induced cardiomyocyte contractile dysfunction. The effect of ghrelin was eliminated by [D-Lys3]-GHRP-6 and Wortmannin. (Fig. 3).

Ghrelin Inhibited Systemic and Myocardial Inflammatory Response in CPB Rats

Previous studies demonstrated that TNF-α and IL-6 are multifunctional pro-inflammatory cytokines regulating neutrophil infiltration [16,17]. Therefore, we examined serum and cardiac TNF-α and IL-6 concentrations. Before the initiation of CPB, serum IL-6 and TNF-α were not detectable in any of the groups. Serum TNF-α and IL-6 levels were increased significantly in the vehicle CPB group, and ghrelin treatment...
Table 1. Effects of ghrelin on cardiac function in different groups after CPB (n = 8, mean ± SEM).

| Group    | HR (beats/min) | MAP (mmHg) | LVDP (mmHg) | +LVdp/dtmax (mmHg/s) | −LVdp/dtmax (mHg/s) |
|----------|----------------|------------|-------------|----------------------|---------------------|
| Sham     | 331 ± 10       | 97 ± 9     | 101 ± 12    | 3211 ± 157           | 2864 ± 184          |
| CPB      | 327 ± 15       | 61 ± 7*    | 68 ± 8*     | 2654 ± 117*          | 2357 ± 147*         |
| CPB+G    | 335 ± 11       | 81 ± 8**   | 89 ± 11**   | 2907 ± 168**         | 2629 ± 142**        |
| CPB+G+GI | 329 ± 17       | 68 ± 5**   | 74 ± 9**    | 2743 ± 134**         | 2417 ± 162**        |
| CPB+G+W  | 328 ± 13       | 65 ± 7**   | 72 ± 10**   | 2711 ± 139**         | 2397 ± 154**        |

G, ghrelin; GI, [D-Lys3]-GHRP-6, ghrelin inhibitor; W, wortmannin, a PI3K inhibitor; HR, heart rate; MAP, mean arterial blood pressure; LVDP, left ventricular developed pressure; +LVdp/dtmax, the instantaneous first derivation of left ventricle pressure.

*P < 0.05 vs. Sham, **P < 0.05 vs. CPB, ***P < 0.05 vs. CPB+G.

doi:10.1371/journal.pone.0055021.t001

Figure 3. Cardiomyocyte contractile properties following CPB. (A) Resting cell length; (B) peak shortening (PS, normalized to cell length); (C) maximal velocity of shortening (+dL/dt); (D) maximal velocity of relaxation (−dL/dt); (E) time-to-PS (TPS) and (F) time-to-90% relaxation (TR90). Values presented are mean ± SEM, n = 68–74 cells for each group from four rats per group. G, ghrelin; GI, [D-Lys3]-GHRP-6, ghrelin inhibitor; W, wortmannin, a PI3K inhibitor. *P < 0.05 vs. Sham, **P < 0.05 vs. CPB, ***P < 0.05 vs. CPB+G.

doi:10.1371/journal.pone.0055021.g003
attenuated this increase ($P<0.01$ for both, Fig. 4A and C). In myocardial extracts, CPB increased the production of TNF-α and IL-6 significantly. Compared with vehicle CPB group, ghrelin treatment significantly decreased tissue levels of TNF-α and IL-6 (Fig. 4B and D; both $P<0.01$). The effect of ghrelin was abolished by [D-Lys3]-GHRP-6 and Wortmanin. These data suggest that ghrelin reduces the systemic and myocardial inflammatory responses in CPB.

Ghrelin Decreased Cardiomyocyte Injury Following Simulated CPB

Our in vivo evidence indicated that ghrelin may exert its cardioprotective effect via a novel anti-inflammatory mechanism. To determine if there was also a direct effect on myocyte function, we cultured neonatal cardiomyocytes and subjected the cells to 6 h of SCPB. As shown in Fig. 5A, SCPB decreased cell viability compared to normal culture conditions ($P<0.05$) and ghrelin increased cell viability ($P<0.05$). Apoptosis is the major form of myocyte cell death after CPB. To investigate whether ghrelin decreased myocardial apoptosis after SCPB, the apoptotic myocytes/total number in cultured cardiomyocytes were determined. In cardiomyocytes from normal culture conditions, there was a very low rate of apoptosis. In contrast, a significant number of apoptotic cells were observed in cardiomyocytes subjected to SCPB. Treatment of ghrelin shortly before SCPB reduced the percentage of apoptotic myocytes (Fig. 5B; $P<0.01$). The effect of ghrelin was blocked by [D-Lys3]-GHRP-6 and Wortmanin.

Activation of GHSR-1a Activated Akt Through Phosphatidylinositol 3'-kinase (PI3K)

Ghrelin treatment resulted in increased Akt phosphorylation both in vivo and in vitro (Fig. 6). To further investigate the mechanisms underlying the ghrelin-induced anti-inflammatory effects, we measured Akt expression and Akt phosphorylation by immunoblotting of myocardial protein extracts from rats at the end of the in vivo experiment and from protein extracts from cultured cardiomyocytes exposed to SCPB (Fig. 6). There was no significant difference in total Akt levels among the different groups, whereas treatment with ghrelin significantly increased the phosphorylation of Akt ($P<0.01$). Pretreatment with [D-Lys3]-GHRP-6 and wortmannin completely blocked the Akt phosphorylation induced by ghrelin (both $P<0.01$). These results demonstrated that both in vivo and in vitro treatment with ghrelin at the onset of CPB increased Akt phosphorylation and Akt activity through the activation of both GHSR-1a and PI3-kinase pathways.

Discussion

Several important observations were made from the present study. First, we provided direct in vivo evidence that ghrelin inhibited systemic and local inflammatory responses in CPB rats. Second, we demonstrated for the first time that in vivo treatment with ghrelin attenuated myocardial injury by reducing CPB-induced apoptosis, decreasing oxidative stress and myocardial injury markers, and preserving cardiac pump function. Third, we have also demonstrated that in vitro treatment with ghrelin exerted cardioprotective effect on cultured myocytes exposed to a simulat-
ed cardiopulmonary bypass environment. Finally, we have shown that ghrelin protected the heart undergoing cardiopulmonary bypass against systemic and local inflammatory responses via activation of GHSR-1a and Akt.

Inflammatory responses, including cytokine induction and neutrophil infiltration, play a critical role in CPB-induced myocardial injury. Several anti-inflammatory procedures and pharmacological agents have been used in cardiac surgery to attenuate myocardial inflammatory injury, including the use of leukocyte filtration, corticosteroids, aprotinin, heparin, and nitrogen monoxidum donor compounds [32]. Despite the relatively small number of studies investigating the effects of reducing the inflammatory response on myocardial injury, the vast majority of these studies have shown that therapies targeting myocardial inflammatory response are beneficial in salvaging myocardium. A prospective observational study has shown that ghrelin likely exerts an inhibitory effect on multiple immune cell types. Based on these observations, immune cells are affected by ghrelin treatment in CPB rats. Likewise, MPO activity was elevated, consistent with neutrophil accumulation, in myocardial tissue following CPB. Ghrelin treatment also reduced MPO activity. Taken together, ghrelin suppressed the inflammatory response to CPB. Furthermore, ghrelin treatment increased GSH levels and decreased GSSG levels, indicating that ghrelin could counteract oxidative stress induced by CPB. These effects may explain the improved cardiac pump function, as ghrelin significantly increased MAP, LVDP, $+\text{LV dP/dt}_\text{max}$, and -$\text{LV dP/dt}_\text{max}$ in vivo and cardiomyocyte contractile function compared with the CPB group.

Our data showed that ghrelin given at the onset of CPB exerted an overall beneficial effect. Open-heart surgery triggers an inflammatory response that is largely the result of global ischaemia during CPB followed by reperfusion injury that occurs following CPB. The heart sustains injury triggered by ischaemia and reperfusion as a result of the effects of systemic inflammatory mediators [2]. Several studies have demonstrated that ghrelin could protect the myocardium against ischaemia/reperfusion injury and improve post-myocardium infarction prognosis [8,35]. In vitro treatment with ghrelin significantly decreased apoptosis in

![Figure 5. Cell viability and apoptosis of simulated CPB cardiomyocytes following different treatments.](image)

A, cell viability measured by MTT assay (n = 8). B, apoptosis measured by in situ detection of TUNEL-positive nuclei and apoptotic index expressed as the percentage of TUNEL-positive nuclei determined by 4',6-diamino-2-phenylindole staining (bottom row) (×20 objective). (n = 8). Values presented are mean ± SEM. Normal, normal culture condition; SCPB, simulated CPB; G, ghrelin; GI, [D-Lys3]-GHRP-6, ghrelin inhibitor; W, wortmannin, a PI3K inhibitor. **P < 0.01 vs. Sham, *P < 0.05 vs. Sham. ***P < 0.01 vs. CPB, **P < 0.05 vs. CPB. δδP < 0.01 vs. CPB+G, δP < 0.05 vs. CPB+G.
cardiomyocytes exposed to simulated CPB, which strongly suggests that ghrelin exerts also cardioprotective effects through direct effects on cardiomyocyte viability.

Previous studies have indicated that the PI3K/Akt pathway serves as a negative regulator for inflammatory genes in monocytes [36], macrophages [37], and endothelial cells [38]. In our study, we found that both in vivo and in vitro treatment with ghrelin significantly increased phosphorylation of Akt. The functional involvement of PI3K/Akt signaling pathways in the cardioprotective effects of ghrelin were demonstrated by the PI3K inhibitor wortmannin. These results suggest that PI3K/Akt pathway is an independent signaling pathway downstream of ghrelin. To our knowledge, the present study is the first to demonstrate that in vivo and in vitro treatment with ghrelin exerts cardioprotective effects against cardiomyocyte injury by stimulating the PI3K/Akt pathway.

GHSR is a seven-transmembrane G protein-coupled receptor for ghrelin, and stimulation of GHSR with ghrelin leads to activation of G protein, calcium mobilization, and multiple downstream signaling. Many biological actions of ghrelin are initiated by binding of ghrelin to its cognate cell surface receptor GHSR-1a [4,39,40]. The GHSR-1a inhibitor [D-Lys3]-GHRP-6 efficiently blocked ghrelin-induced phosphorylation of Akt and in vitro cardioprotective effects, suggesting that ghrelin exerts effects through a receptor linked to GHSR-1a. These results suggest that PI3K/Akt signaling pathway is GHSR-1a-mediated involved in the cardioprotective effects of ghrelin.

Recent data suggest a relevant role of peptides encoded by the ghrelin gene in protecting heart from ischemia, inflammation and oxidation. Obestatin, another peptide mediator deriving together with ghrelin from pre-proGhrelin, exerts remarkable protective effects against myocardial injury, apoptotic cell death and contractile dysfunction induced by ischemia and reperfusion in the heart. Besides to the PI3K/Akt pathway activation, the protective effect of obestatin has been related to stimulation of other reperfusion injury salvage kinases (RISK), such as PKC and ERK 1/2 [41]. Circulating levels of ghrelin or proghrelin-derived peptides are altered in cardiovascular diseases such as cardiac ischemia, type 2 diabetes mellitus and obesity [42,43,44]. All of above suggest the critical role of ghrelin in myocardial protection both under physiological and pathological conditions.

In conclusion, we have demonstrated that ghrelin inhibits CPB-induced systemic and local inflammatory mediator production through the GHSR-1a activated and PI3K/Akt-dependent pathway, which results in cardioprotection in response to CPB. The anti-inflammatory property elicited by ghrelin, together with its metabolic modulation, anti-apoptosis, anti-oxidant, and vasculo-protection mechanisms [15], implicate ghrelin as a versatile and effective drug not only in CPB but also in other inflammatory diseases, including stroke, sepsis, and shock [9,10].

Author Contributions
Conceived and designed the experiments: SQY DHY CHG. Performed the experiments: YKC JT. Analyzed the data: HM. Contributed reagents/materials/analysis tools: YKC JT TY. Wrote the paper: YKC SQY.

References
1. Freyholdt T, Massoudy P, Zahler S, Henze R, Barankay A, et al. (2003) Beneficial effect of sodium nitroprusside after coronary artery bypass surgery: pump function correlates inversely with cardiac release of proinflammatory cytokines. J Cardiovasc Pharmacol 42: 372–378.
2. Suleiman MS, Zacharowski K, Angelini GD (2008) Inflammatory response and cardioprotection during open-heart surgery: the importance of anaesthetics. Br J Pharmacol 153: 21–33.
3. Raja SG, Dreyfus GD (2005) Modulation of systemic inflammatory response after cardiac surgery. Asian Cardiovasc Thorac Ann 13: 382–395.
4. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, et al. (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402: 656–660.

5. Smith RG, Leonard R, Bailey AR, Palyha O, Feighner S, et al. (2001) Growth hormone secretagogue receptor family members and ligands. Endocrine 14: 9–14.

6. Locatelli V, Rossoni G, Schweiger F, Torsello A, De Gennaro Colonna V, et al. (1999) Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 140: 4021–4031.

7. Frascarelli S, Ghelardoni S, Ronca-Testoni S, Zucchi R (2003) Effect of ghrelin and synthetic growth hormone secretagogues in normal and ischemic rat heart. Basic Res Cardiol 98: 401–405.

8. Chang L, Ren Y, Liu X, Li WG, Yang J, et al. (2004) Protective effects of ghrelin on ischemia/reperfusion injury in the isolated rat heart. J Cardiovasc Pharmacol 43: 165–170.

9. Wu R, Dong W, Cui X, Zhou M, Simms HH, et al. (2007) Ghrelin down-regulates proinflammatory cytokines in sepsis through activation of the vagus nerve. Ann Surg 245: 480–486.

10. Chang L, Zhao J, Yang J, Zhang Z, Du J, et al. (2003) Therapeutic effects of ghrelin on endotoxic shock in rats. Eur J Pharmacol 473: 171–176.

11. Kantorova E, Chomova M, Kurca E, Sivak S, Zelenak K, et al. (2011) Leptin, adiponectin and ghrelin, new potential mediators of ischemic stroke. Neuro Endocrinol Lett 32: 716–721.

12. Choyasu C, Wu R, Zhou M, Jacob A, Coppa G, et al. (2011) Ghrelin suppresses inflammation and neuronal nitric oxide synthase in focal cerebral ischemia via the vagus nerve. Shock 35: 258–263.

13. Schwere DO, Tokudome T, Kishimoto I, Horio T, Shirai M, et al. (2008) Early ghrelin treatment after myocardial infarction prevents an increase in cardiac sympathetic tone and reduces mortality. Endocrinology 149: 5172–5176.

14. Huang CX, Yuan MJ, Huang W, Gu L, Liu Y, et al. (2009) Ghrelin inhibits post-infarct myocardial remodeling and improves cardiac function through anti-inflammation effect. Peptides 30: 2286–2291.

15. Zhang G, Yin X, Qi Y, Pendyala L, Chen J, et al. (2010) Ghrelin and cardiovascular diseases. Curr Cardiol Rev 6: 62–70.

16. Bazzoni F, Beutler B (1996) The tumor necrosis factor ligand and receptor families. N Engl J Med 334: 1717–1725.

17. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, et al. (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1–20.

18. Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N (2010) Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev 15: 543–562.

19. von Haehling S, Schefold JC, Lainscak M, Doehner W, Anker SD (2009) Inflammatory biomarkers in heart failure revisited: much more than innocent bystanders. Heart Fail Clin 5: 549–560.

20. Yu QJ, Si R, Zhou N, Zhang HF, Guo WY, et al. (2008) Insulin inhibits tumor necrosis factor-alpha and interleukin-1beta synergistically depress human myocardial function. Crit Care Med 27: 1309–1318.

21. Ji L, Fu F, Zhang L, Liu X, Li WG, et al. (2004) Protective effects of ghrelin in cardiopulmonary bypass with excellent survival. J Surg Res 123: 171–175.

22. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, et al. (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1–20.

23. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, et al. (1992) Negative inotropic effects of cytokines on the heart mediated by nitric oxide and platelet-activating factor in cardiac alterations induced by tumor cardiopulmonary bypass. Cytokine 44: 96–100.

24. Dong GH, Xu B, Wang CT, Qian JJ, Liu H, et al. (2005) A rat model of cardiopulmonary bypass with excellent survival. J Surg Res 123: 171–175.

25. Zhu J, Yin R, Shao H, Dong G, Luo L, et al. (2007) N-acetylcycteine to ameliorate acute renal injury in a rat cardiopulmonary bypass model. J Thorac Cardiovasc Surg 133: 696–703.

26. Li J, Zhang H, Wu F, Nau Y, Ma H, et al. (2008) Insulin inhibits tumor necrosis factor-alpha induction in myocardial ischemia/reperfusion: role of Akt and endothelial nitric oxide synthase phosphorylation. Crit Care Med 36: 1551–1558.

27. Qi X, Si R, Zhou N, Zhang HF, Gao WY, et al. (2008) Insulin inhibits beta-adrenergic action in ischemic/reperfused heart: a novel mechanism of insulin in cardioprotection. Apoptosis 13: 305–317.

28. Su H, Sun X, Ma H, Zhang HF, Yu QJ, et al. (2007) Acute hyperglycemia exaggerates myocardial ischemia/reperfusion injury and blunts cardioprotective effect of GIK. Am J Physiol Endocrinol Metab 293: E629–E635.

29. Li J, Fu F, Zhang L, Liu W, Cai X, et al. (2010) Insulin attenuates myocardial ischemia/reperfusion injury via reducing oxidative/nitritive stress. Am J Physiol Endocrinol Metab 298: E671–E800.

30. Yue TL, Wang G, Gu JL, Ma XL, Kumar S, et al. (2000) Inhibition of extracellular signal-regulated kinase enhances ischemia/Reoxygenation-induced apoptosis in cultured cardiac myocytes and exaggerates reperfusion injury in the isolated perfused rat heart. Circ Res 86: 692–699.

31. Aebert H, Karchner S, Keyser A, Birnbaum DE, Holler E, et al. (2000) Endothelial apoptosis is induced by serum of patients after cardiopulmonary bypass. Eur J Cardiothorac Surg 18: 589–593.

32. Asumakopoulos G, Gourlay T (2003) A review of anti-inflammatory strategies in cardiac surgery. Perfusion 18 Suppl 1: 7–12.

33. de Mendonca-Filho HT, Pereira KC, Fontes M, Vieira DA, de Mendonca ML, et al. (2006) Circulating inflammatory mediators and organ dysfunction after cardiovascular surgery with cardiopulmonary bypass: a prospective observational study. Crit Care 10: R46.

34. Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciaccio G, et al. (2006) Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery. Crit Care Med 34: 660–667.

35. Soeki T, Kishimoto I, Schwenke DO, Tokudome T, Horio T, et al. (2008) Ghrelin suppresses cardiac sympathetic activity and prevents early left ventricular remodeling in rats with myocardial infarction. Am J Physiol Heart Circ Physiol 294: H125–H132.

36. Grolla M, Mackman N (2007) The phosphatidylinositol 3-kinase-Akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human mononuclear cells. J Biol Chem 277: 32124–32132.

37. Tengku-Muhammad TS, Hughes TR, Ceyer A, Rammig DP (1999) Involvement of both the tyrosine kinase and the phosphatidylinositol-3-kinase signal transduction pathways in the regulation of lipopolysaccharide expression in J774.2 macrophages by cytokines and lipopolysaccharide. Cytokine 11: 463–468.

38. Kim I, Oh JL, Rya VN, So JN, Seo WC, et al. (2002) Angiotensin-I negatively regulates expression and activity of tissue factor in endothelial cells. FASEB J 16: 126–128.

39. Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, et al. (2001) A role for ghrelin in the central regulation of feeding. Nature 409: 194–198.

40. Tsophr M, Smiley DL, Heimlan ML (2000) Ghrelin induces adiposity in rodents. Nature 407: 908–913.

41. Allolio G, Arrolleti E, Bassino E, Penna C, Perrelli MG, et al. (2010) Obestatin affords cardioprotection to the ischemic-reperfused isolated rat heart and inhibits apoptosis in cultures of similarly stressed cardiomyocytes. Am J Physiol Heart Circ Physiol 299: H470–481.

42. Ozbay Y, Aydin S, Dogl AF, Akbulut M, Dogl N, et al. (2008) Obestatin is present in saliva: alterations in obestatin and ghrelin levels of saliva and serum in ischemic heart disease. BMR Rep 41: 55–61.

43. Qi X, Li L, Yang G, Liu J, Li K, et al. (2007) Circulating obestatin levels in normal subjects and in patients with impaired glucose regulation and type 2 diabetes mellitus. Clin Endocrinol (Oxf) 66: 593–597.

44. Huda MS, Durham BH, Wong SP, Deepak D, Kerejian D, et al. (2008) Plasma obestatin levels are lower in obese and post-gastrectomy subjects, but do not change in response to a meal. Int J Obes (Lond) 32: 129–135.